Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Long-term evolution and predictive factors of mild inflammatory bowel disease.

Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E.

Scand J Gastroenterol. 2016;51(6):712-9. doi: 10.3109/00365521.2015.1128965. Epub 2016 Jan 27.

2.

Persisting signs of disease activity at Magnetic Resonance Enterocolonography predict clinical relapse and disease progression in quiescent Crohn's disease.

Meunier P, Cousin F, Van Kemseke C, Reenaers C, Latour P, Belaiche J, Seidel L, Louis E.

Acta Gastroenterol Belg. 2015 Jul-Sep;78(3):274-81.

PMID:
26448407
3.

[FROM EVIDENCE-BASED MEDICINE TO PERSONALIZED MEDICINE IN CROHN'S DISEASE].

Louis E, Reenaers C, Van Kemseke C, Latour P, Belaiche J, Meunier P, Coïmbra C.

Rev Med Liege. 2015 May-Jun;70(5-6):316-20. Review. French.

4.

Depth of remission in Crohn's disease patients seen in a referral centre : associated factors and impact on disease outcome.

Poncin M, Reenaers C, Van Kemseke C, Belaiche J, Seidel L, Meunier P, Louis E.

Acta Gastroenterol Belg. 2014 Mar;77(1):41-6.

PMID:
24761690
5.

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.

De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, Dʼhaens GR, Franchimont D, Baert FJ, Torp RA, Henriksen M, Potvin PM, Van Hootegem PP, Hindryckx PM, Moreels TG, Collard A, Karlsen LN, Kittang E, Lambrecht G, Grimstad T, Koch J, Lygren I, Coche JC, Mana F, Van Gossum A, Belaiche J, Cool MR, Fontaine F, Maisin JM, Muls V, Neuville B, Staessen DA, Van Assche GA, de Lange T, Solberg IC, Vander Cruyssen BJ, Vermeire SA.

Inflamm Bowel Dis. 2013 Sep;19(10):2111-7. doi: 10.1097/MIB.0b013e31829b2a37.

PMID:
23883959
6.

Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.

Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S.

Aliment Pharmacol Ther. 2013 Apr;37(7):752-3. doi: 10.1111/apt.12245. No abstract available.

7.

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S.

Aliment Pharmacol Ther. 2012 Dec;36(11-12):1040-8. doi: 10.1111/apt.12076. Epub 2012 Oct 14.

8.

[Genetics and environment in chronic inflammatory bowel diseases].

Louis E, Van Kemseke C, Latour P, Belaiche J, Reenaers C.

Rev Med Liege. 2012 May-Jun;67(5-6):298-304. Review. French.

9.

Impact of medical therapies on inflammatory bowel disease complication rate.

Reenaers C, Belaiche J, Louis E.

World J Gastroenterol. 2012 Aug 7;18(29):3823-7. doi: 10.3748/wjg.v18.i29.3823. Review.

10.

[Fifteen years of use of anti-TNF antibodies in moderate to severe Crohn's disease: how to make the best of this experience].

Louis E, Reenaers C, Meuwis MA, Van Kemseke C, Latour P, Chapelier N, Wertz S, Coïmbra C, Meunier P, Belaiche J.

Rev Med Liege. 2012;67 Spec No:8-13. French.

11.

Hepatitis C of genotype 2: the role of medical invasive exams.

Putzeys V, Gérard C, Bastens B, Wain E, Bataille C, Defrance P, Belaiche J, Delwaide J, Belaiche J, Delwaide J, de Roover A, Detry O, Gérard C, Honoré P, Maggipinto G, Rentier B, Vaira D; Groupe Liégeois d'Etude des Virus Hépatotropes.

Acta Gastroenterol Belg. 2011 Jun;74(2):277-80.

12.

Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.

Bello C, Belaiche J, Louis E, Reenaers C.

J Crohns Colitis. 2011 Jun;5(3):196-202. doi: 10.1016/j.crohns.2010.12.011. Epub 2011 Feb 10.

13.

[Clinical case of the month. Cystic lymphangioma of the mesentery].

Verdin V, Seydel B, Detry O, Van Daele D, Meunier P, Honoré P, Meurisse M, Belaïche J.

Rev Med Liege. 2010 Nov;65(11):615-8. French.

14.

Current directions of biologic therapies in inflammatory bowel disease.

Reenaers C, Louis E, Belaiche J.

Therap Adv Gastroenterol. 2010 Mar;3(2):99-106. doi: 10.1177/1756283X09356872.

15.

[Challenges to reduce mortality due to hepatitis C: improving accessibility to therapy and compliance].

Delwaide J, Lamproye A, Belaïche J.

Rev Med Liege. 2010 May-Jun;65(5-6):354-7. French.

16.

Do clinical factors help to predict disease course in inflammatory bowel disease?

Louis E, Belaiche J, Reenaers C.

World J Gastroenterol. 2010 Jun 7;16(21):2600-3.

17.

Anti-TNF and Crohn's disease: when should we stop?

Louis E, Belaiche J, Reenaers C.

Curr Drug Targets. 2010 Feb;11(2):148-51.

PMID:
20210763
18.

[Genomics of inflammatory bowel diseases: basis for a new molecular classification and new therapeutic strategies of these diseases].

Louis E, Libioulle C, Reenaers C, Belaiche J, Georges M.

Rev Med Liege. 2009;64 Spec No:24-8. French.

19.

Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?

Reenaers C, Belaiche J, Louis E.

Inflamm Bowel Dis. 2010 Aug;16(8):1271-2. doi: 10.1002/ibd.21162. No abstract available.

20.

Common variants at five new loci associated with early-onset inflammatory bowel disease.

Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, Kugathasan S, Bradfield JP, Walters TD, Sleiman P, Kim CE, Muise A, Wang K, Glessner JT, Saeed S, Zhang H, Frackelton EC, Hou C, Flory JH, Otieno G, Chiavacci RM, Grundmeier R, Castro M, Latiano A, Dallapiccola B, Stempak J, Abrams DJ, Taylor K, McGovern D; Western Regional Alliance for Pediatric IBD, Silber G, Wrobel I, Quiros A; International IBD Genetics Consortium, Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmuda MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwillam R, Tremelling M, Delukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ, Heyman MB, Ferry GD, Kirschner B, Lee J, Essers J, Grand R, Stephens M, Levine A, Piccoli D, Van Limbergen J, Cucchiara S, Monos DS, Guthery SL, Denson L, Wilson DC, Grant SF, Daly M, Silverberg MS, Satsangi J, Hakonarson H.

Nat Genet. 2009 Dec;41(12):1335-40. doi: 10.1038/ng.489. Epub 2009 Nov 15.

21.

Anti-tumor necrosis factor nonresponders in Crohn's disease: therapeutic strategies.

Louis E, Belaiche J, Reenaers C.

Dig Dis. 2009;27(3):351-7. doi: 10.1159/000228573. Epub 2009 Sep 24. Review.

PMID:
19786764
22.

Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis.

Villani AC, Lemire M, Louis E, Silverberg MS, Collette C, Fortin G, Nimmo ER, Renaud Y, Brunet S, Libioulle C, Belaiche J, Bitton A, Gaudet D, Cohen A, Langelier D, Rioux JD, Arnott ID, Wild GE, Rutgeerts P, Satsangi J, Vermeire S, Hudson TJ, Franchimont D.

PLoS One. 2009 Sep 28;4(9):e7154. doi: 10.1371/journal.pone.0007154.

23.

[Adenocarcinoma of the small intestines complicating coeliac disease in an adult: case report].

Ausloos F, Scagnol I, Belaiche J.

Rev Med Liege. 2009 Jul-Aug;64(7-8):394-7. French.

24.

Genetics of ulcerative colitis: the come-back of interleukin 10.

Louis E, Libioulle C, Reenaers C, Belaiche J, Georges M.

Gut. 2009 Sep;58(9):1173-6. doi: 10.1136/gut.2008.169235. No abstract available.

25.

[Biologic therapies in chronic inflammatory bowel diseases].

Reenaers C, Louis E, Belaiche J.

Rev Med Liege. 2009 May-Jun;64(5-6):301-4. French.

26.

[Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].

Piront P, Van Daele D, Belaiche J, Polus M.

Rev Med Liege. 2009 May-Jun;64(5-6):274-8. French.

27.

Tailoring the treatment to the individual in Crohn's disease.

Louis E, Belaiche J, Reenaers C.

Therap Adv Gastroenterol. 2009 Jul;2(4):239-44. doi: 10.1177/1756283X09337180.

28.

[Treatment of (unresectable) hepatocellular carcinoma at an intermediate or advanced stage].

Van Daele D, Belaiche J, Delwaide J, Piront P, De Roover A, Detry O, Honoré P, Polus M.

Rev Med Liege. 2009 Mar;64(3):140-7. Review. French.

29.

[Colorectal cancer screening: an absolute necessity and a concrete reality in the French community].

Polus M, Montrieux C, Giet D, Louis E, Belaiche J, Coche E.

Rev Med Liege. 2009 Feb;64(2):96-102. French.

30.

Guillain-Barré syndrome following hepatitis E.

Loly JP, Rikir E, Seivert M, Legros E, Defrance P, Belaiche J, Moonen G, Delwaide J.

World J Gastroenterol. 2009 Apr 7;15(13):1645-7.

31.

Common variants in the NLRP3 region contribute to Crohn's disease susceptibility.

Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, Baba N, Libioulle C, Belaiche J, Bitton A, Gaudet D, Cohen A, Langelier D, Fortin PR, Wither JE, Sarfati M, Rutgeerts P, Rioux JD, Vermeire S, Hudson TJ, Franchimont D.

Nat Genet. 2009 Jan;41(1):71-6. doi: 10.1038/ng.285. Epub 2008 Dec 21.

32.

Predictors of severe Crohn's disease.

Loly C, Belaiche J, Louis E.

Scand J Gastroenterol. 2008 Aug;43(8):948-54.

PMID:
19086165
33.

[Hepatitis E: a Third World's hepatitis found in Belgium].

Seivert M, Belaiche J, Delwaide J.

Rev Med Liege. 2008 Sep;63(9):549-53. French.

34.

Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease.

Reenaers C, Franchimont N, Oury C, Belaiche J, Malaise M, Bours V, Theatre E, Delvenne P, Louis E.

Scand J Gastroenterol. 2008;43(11):1334-45. doi: 10.1080/00365520802200010.

35.

Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohn's disease?

Louis E, Reenaers C, Belaiche J.

Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S59-60. doi: 10.1002/ibd.20559. No abstract available. Erratum in: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47.

36.

Does the behavior of Crohn's disease change over time?

Louis E, Reenaers C, Belaiche J.

Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S54-5. doi: 10.1002/ibd.20561. No abstract available. Erratum in: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47.

37.

Are we giving biologics too much time? When should we stop treatment?

Louis E, Belaiche J, Reenaers C.

World J Gastroenterol. 2008 Sep 28;14(36):5528-31. Review.

38.

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.

Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ.

Nat Genet. 2008 Aug;40(8):955-62. doi: 10.1038/ng.175. Epub 2008 Jun 29.

39.

[Eosinophilic esophagitis in adults: report of a case].

Marting A, Leclercq P, Gast P, Scagnol I, Belaiche J.

Rev Med Liege. 2008 Apr;63(4):184-6. French.

40.

Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.

Meuwis MA, Fillet M, Lutteri L, Marée R, Geurts P, de Seny D, Malaise M, Chapelle JP, Wehenkel L, Belaiche J, Merville MP, Louis E.

Clin Biochem. 2008 Aug;41(12):960-7. doi: 10.1016/j.clinbiochem.2008.04.021. Epub 2008 May 6.

41.

[The FibroScan: a new non invasive method of liver fibrosis evaluation].

Lamproye A, Belaiche J, Delwaide J.

Rev Med Liege. 2007;62 Spec No:68-72. Review. French.

42.

[Innovative therapies in inflammatory bowel disease at the CHU].

Belaiche J, Chapelier N, Wertz S, Louis E.

Rev Med Liege. 2007;62 Spec No:63-7. Review. French.

43.

An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases.

Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, Wiman AC, Vermeire S, Rutgeerts P, Belaiche J, Franchimont D, Van Gossum A, Bours V, Syvänen AC.

Hum Mol Genet. 2007 Dec 15;16(24):3008-16. Epub 2007 Sep 19.

44.

Clinical and genetic factors associated with sacroiliitis in Crohn's disease.

Peeters H, Vander Cruyssen B, Mielants H, de Vlam K, Vermeire S, Louis E, Rutgeerts P, Belaiche J, De Vos M.

J Gastroenterol Hepatol. 2008 Jan;23(1):132-7. Epub 2007 Aug 27.

45.

[Recent advances in liver surgery and transplantation].

Detry O, De Roover A, Coimbra C, Detroz B, Delwaide J, Kaba A, Polus M, Lamproye A, Joris J, Belaïche J, Meurisse M, Honoré P.

Rev Med Liege. 2007 May-Jun;62(5-6):310-6. Review. French.

46.

[Therapeutic update in gastroenterology].

Belaiche J, Delwaide J, Polus M, Louis E.

Rev Med Liege. 2007 May-Jun;62(5-6):303-9. Review. French.

47.

Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT.

Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R.

J Nucl Med. 2007 Jul;48(7):1053-9. Epub 2007 Jun 15.

48.

The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases.

De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, Belaiche J, Vermeire S, Farwell L, Goris A, Libioulle C, Jani N, Dassopoulos T, Bromfield GP, Dubois B, Cho JH, Brant SR, Duerr RH, Yang H, Rotter JI, Silverberg MS, Steinhart AH, Daly MJ, Podolsky DK, Louis E, Hafler DA, Rioux JD; Quebec IBD Genetics Consortium; NIDDK IBD Genetics Consortium.

Genes Immun. 2007 Jul;8(5):387-97. Epub 2007 May 31.

49.
50.

Cadaveric liver transplantation for non-acetaminophen fulminant hepatic failure: a 20-year experience.

Detry O, De Roover A, Coimbra C, Delwaide J, Hans MF, Delbouille MH, Monard J, Joris J, Damas P, Belaïche J, Meurisse M, Honoré P.

World J Gastroenterol. 2007 Mar 7;13(9):1427-30.

Supplemental Content

Loading ...
Support Center